Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03787680 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv20
  2. Study completion date: Jan 2027 to Aug 2028v19
  3. Results first posted: Aug 12, 2024v18
  4. 3 versions Re-verified since Mar 13, 2024, no change to tracked fieldsv15-v17
  5. Secondary endpoints revised (13)
    • Primary endpoint revised
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date changed from estimate of Feb 2023 to Jan 26, 2023
    • Study completion date: Feb 2027 to Jan 2027
    v13
  2. Primary completion date: Nov 2022 to Feb 2023
    • Study completion date: Nov 2026 to Feb 2027
    v12
  3. Primary completion date: Jun 2022 to Nov 2022
    • Study completion date: Nov 2025 to Nov 2026
    v11
  4. Primary completion date: Nov 2021 to Jun 2022v10
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 47 to confirmed 49
    • Study sites: 2 to 3
    • Eligibility criteria expanded, about 34 words
    v9
  6. Site details revised at 1 of 2 sitesv8
  7. Start date changed from estimate of Nov 2019 to Oct 31, 2019v7
  8. Study sites: 1 to 2v6
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2019 to Nov 2019
    • Site details revised
    v5
  10. Start date: Jun 2019 to Oct 2019
    • Primary completion date: Jul 2021 to Nov 2021
    • Study completion date: Jul 2025 to Nov 2025
    v4
  11. Start date: Apr 2019 to Jun 2019v3
  12. Start date: Feb 2019 to Apr 2019
    • Primary completion date: May 2021 to Jul 2021
    • Study completion date: May 2025 to Jul 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.
Trial Details
NCT Number NCT03787680
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov